InflaRx’s (IFRX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of InflaRx (NASDAQ:IFRX) in a report issued on Friday morning, MarketBeat Ratings reports. HC Wainwright currently has a $8.00 price target on the stock.

InflaRx Trading Up 1.6 %

IFRX stock opened at $1.28 on Friday. The firm has a 50 day moving average of $1.92 and a 200-day moving average of $1.90. InflaRx has a 12-month low of $1.13 and a 12-month high of $2.82. The company has a market cap of $85.93 million, a price-to-earnings ratio of -1.19 and a beta of 1.98.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. Sell-side analysts forecast that InflaRx will post -1.04 earnings per share for the current fiscal year.

Institutional Trading of InflaRx

Several hedge funds and other institutional investors have recently bought and sold shares of IFRX. Two Sigma Securities LLC purchased a new stake in InflaRx in the 4th quarter worth approximately $28,000. Walleye Capital LLC acquired a new position in shares of InflaRx in the 4th quarter valued at $51,000. Cubist Systematic Strategies LLC acquired a new position in shares of InflaRx during the 4th quarter valued at $55,000. Geode Capital Management LLC lifted its holdings in shares of InflaRx by 32.8% during the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after acquiring an additional 11,900 shares in the last quarter. Finally, Commonwealth Equity Services LLC lifted its holdings in shares of InflaRx by 20.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock valued at $275,000 after acquiring an additional 19,000 shares in the last quarter. 42.39% of the stock is owned by hedge funds and other institutional investors.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.